Veraxa Biotech AG Company Profile
NASDAQ: VRXAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Veraxa Biotech at a glance
Veraxa Biotech AG (NASDAQ: VRXA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Zurich, Switzerland. Veraxa Biotech is led by Dr. Christoph Antz Ph.D.. At a market capitalization of $145.7 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0002079109, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Veraxa Biotech do?
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Zurich, Switzerland.
Business description based on the company's public filings.
Company information
- Legal name
- Veraxa Biotech AG
- Ticker
- NASDAQ: VRXA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christoph Antz Ph.D.
- Headquarters
- Talacker 35, Zurich, Switzerland
- Phone
- 49 6221 3521330
- Website
- veraxa.com
- Market cap
- $145.65M
- SEC CIK
- 0002079109
Companies similar to Veraxa Biotech
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs VRXA |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs VRXA |
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs VRXA |
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs VRXA |
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs VRXA |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs VRXA |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs VRXA |
| ZNTLZentalis Pharmaceuticals Inc. | 1.36 | 0.00% | $133.64M | vs VRXA |